Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland B Walter

Showing results (11-20 of 282) with videos related to

Pageof 29
Sort By:
Expert Opinion on Biological Therapy|March 30, 2022
Where do we stand with radioimmunotherapy for acute myeloid leukemia?Roland B Walter
Expert Opinion on Biological Therapy|June 26, 2020
Expanding use of CD33-directed immunotherapyRoland B Walter
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Reply to C.S. Hourigan et alDaisuke Araki, Roland B Walter
Current Opinion in Hematology|December 9, 2016
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?Francesco Buccisano, Roland B Walter
Expert Review of Hematology|January 19, 2016
Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Armin Rashidi, Roland B Walter
European Journal of Haematology|November 13, 2013
Chronic myeloid leukemia in lymphoid blast crisisSindhu Cherian, Roland B Walter
Nature Reviews. Clinical Oncology|May 26, 2018
Next-generation sequencing for measuring minimal residual disease in AMLRoland B Walter, Frederick R Appelbaum
Hematology. American Society of Hematology. Education Program|December 6, 2015
Antigen-specific immunotherapies for acute myeloid leukemiaSarah A Buckley, Roland B Walter
Best Practice & Research. Clinical Haematology|June 18, 2019
Novel monoclonal antibody-based therapies for acute myeloid leukemiaLinde M Morsink, Roland B Walter
Current Hematologic Malignancy Reports|April 22, 2015
Update on antigen-specific immunotherapy of acute myeloid leukemiaSarah A Buckley, Roland B Walter
Pageof 29

Showing results (11-20 of 282) with videos related to

Sort By:
Pageof 29
Expert Opinion on Biological Therapy|March 30, 2022
Where do we stand with radioimmunotherapy for acute myeloid leukemia?Roland B Walter
Expert Opinion on Biological Therapy|June 26, 2020
Expanding use of CD33-directed immunotherapyRoland B Walter
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2016
Reply to C.S. Hourigan et alDaisuke Araki, Roland B Walter
Current Opinion in Hematology|December 9, 2016
Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?Francesco Buccisano, Roland B Walter
Expert Review of Hematology|January 19, 2016
Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?Armin Rashidi, Roland B Walter
European Journal of Haematology|November 13, 2013
Chronic myeloid leukemia in lymphoid blast crisisSindhu Cherian, Roland B Walter
Nature Reviews. Clinical Oncology|May 26, 2018
Next-generation sequencing for measuring minimal residual disease in AMLRoland B Walter, Frederick R Appelbaum
Hematology. American Society of Hematology. Education Program|December 6, 2015
Antigen-specific immunotherapies for acute myeloid leukemiaSarah A Buckley, Roland B Walter
Best Practice & Research. Clinical Haematology|June 18, 2019
Novel monoclonal antibody-based therapies for acute myeloid leukemiaLinde M Morsink, Roland B Walter
Current Hematologic Malignancy Reports|April 22, 2015
Update on antigen-specific immunotherapy of acute myeloid leukemiaSarah A Buckley, Roland B Walter
Pageof 29